In a recent publication, the Sears lab showed that introduction of the BRAFV600E mutation into mice colonized with enterotoxigenic Bacteroides fragilis (ETBF) leads to production of midcolon tumors with similarity to human BRAFV600E tumors and distinct from the ETBF-induced distal adenomas typical for this ETBF mouse model. In particular, the BRAFV600E tumors show sensitivity to anti-PD-L1 treatment, suggesting a line of investigation for improving immunotherapy treatment for colon cancer. Check out this blog, on the Cancer Grand Challenges website, where Cindy discusses this work and its implications.
Kimmie Ng and Marios Giannakis publish a perspective “A Common Cancer at an Uncommon Age”
By 2030 colorectal cancer will be the leading cause of cancer deaths in individuals aged 20-49. Young-onset CRC differs from average age onset. Young-onset disease is often more aggressive, presents on the left side of the colon rather than the right, and often...
